IL264924A - - Google Patents

Info

Publication number
IL264924A
IL264924A IL26492419A IL26492419A IL264924A IL 264924 A IL264924 A IL 264924A IL 26492419 A IL26492419 A IL 26492419A IL 26492419 A IL26492419 A IL 26492419A IL 264924 A IL264924 A IL 264924A
Authority
IL
Israel
Application number
IL26492419A
Other languages
English (en)
Other versions
IL264924B2 (en
IL264924B1 (en
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of IL264924A publication Critical patent/IL264924A/en
Publication of IL264924B1 publication Critical patent/IL264924B1/en
Publication of IL264924B2 publication Critical patent/IL264924B2/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL264924A 2016-08-31 2017-08-24 4–4–TRIFLUORO–N–[(1S)–2–[[(7S–5–(2–HYDROXYETHYL)–6–OXO–7H–PYRIDO[2,3–D][3]BENZAZEPIN–7–YL [AMINO]–1–METHYL–2–OXO–ETHYL]BUTANAMIDE or a salt or hydrate thereof for use in the treatment of solid cancer IL264924B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662381911P 2016-08-31 2016-08-31
PCT/US2017/048308 WO2018044662A1 (en) 2016-08-31 2017-08-24 Dosage regimen for treatment of solid tumors

Publications (3)

Publication Number Publication Date
IL264924A true IL264924A (https=) 2019-04-30
IL264924B1 IL264924B1 (en) 2023-09-01
IL264924B2 IL264924B2 (en) 2024-01-01

Family

ID=59772787

Family Applications (2)

Application Number Title Priority Date Filing Date
IL264924A IL264924B2 (en) 2016-08-31 2017-08-24 4–4–TRIFLUORO–N–[(1S)–2–[[(7S–5–(2–HYDROXYETHYL)–6–OXO–7H–PYRIDO[2,3–D][3]BENZAZEPIN–7–YL [AMINO]–1–METHYL–2–OXO–ETHYL]BUTANAMIDE or a salt or hydrate thereof for use in the treatment of solid cancer
IL305136A IL305136A (en) 2016-08-31 2017-08-24 Dosage regimen for the treatment of solid tumors

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL305136A IL305136A (en) 2016-08-31 2017-08-24 Dosage regimen for the treatment of solid tumors

Country Status (14)

Country Link
US (1) US20190209581A1 (https=)
EP (1) EP3506905B1 (https=)
JP (2) JP2019526632A (https=)
KR (1) KR102512899B1 (https=)
CN (2) CN109562114A (https=)
AU (1) AU2017321011B2 (https=)
BR (1) BR112019002461A2 (https=)
CA (1) CA3035616A1 (https=)
ES (1) ES2977556T3 (https=)
IL (2) IL264924B2 (https=)
MA (1) MA46086A (https=)
MX (1) MX387397B (https=)
SG (2) SG11201901325UA (https=)
WO (1) WO2018044662A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI609687B (zh) 2015-04-14 2018-01-01 美國禮來大藥廠 平滑肌肉瘤之標靶性治療
JP6911047B2 (ja) 2016-04-12 2021-07-28 イーライ リリー アンド カンパニー がんの処置のための、Notch阻害剤およびCDK4/6阻害剤の併用療法
EP3442528B1 (en) 2016-04-12 2021-05-26 Eli Lilly and Company Combination therapy with notch and pi3k/mtor inhibitors for use in treating ovarian cancer
JP7194022B2 (ja) 2016-05-20 2022-12-21 イーライ リリー アンド カンパニー Notch阻害剤とPD-1またはPD-L1阻害剤との併用療法
EP3525796A1 (en) 2016-10-12 2019-08-21 Eli Lilly and Company Targeted treatment of mature t-cell lymphoma
MX2019009552A (es) 2017-02-17 2019-10-02 Hutchinson Fred Cancer Res Terapias de combinacion para el tratamiento de canceres relacionados con el antigeno de maduracion de celulas b (bcma) y trastornos autoinmunitarios.
MX2020004568A (es) 2017-11-06 2020-10-05 Juno Therapeutics Inc Combinación de una terapia celular y un inhibidor de gamma secretasa.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US46206A (en) 1865-02-07 Improved vessel for holding petroleum
WO2008112249A1 (en) * 2007-03-13 2008-09-18 Trustees Of Columbia University In The City Of New York Synergistic interaction of notch-1 inhibitors with glucocorticoids
US20090149433A1 (en) * 2007-11-13 2009-06-11 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
AR087107A1 (es) * 2011-07-27 2014-02-12 Lilly Co Eli Compuesto inhibidor de la señalizacion de la trayectoria notch
CN106488775A (zh) * 2014-07-11 2017-03-08 基因泰克公司 Notch途径抑制
TWI609687B (zh) * 2015-04-14 2018-01-01 美國禮來大藥廠 平滑肌肉瘤之標靶性治療

Also Published As

Publication number Publication date
CN109562114A (zh) 2019-04-02
EP3506905B1 (en) 2024-03-20
EP3506905A1 (en) 2019-07-10
MX387397B (es) 2025-03-18
BR112019002461A2 (pt) 2019-05-14
KR102512899B1 (ko) 2023-03-23
SG11201901325UA (en) 2019-03-28
AU2017321011B2 (en) 2023-08-03
CA3035616A1 (en) 2018-03-08
IL264924B2 (en) 2024-01-01
ES2977556T3 (es) 2024-08-26
MX2019002066A (es) 2019-06-03
MA46086A (fr) 2019-07-10
SG10202107832UA (en) 2021-09-29
WO2018044662A1 (en) 2018-03-08
JP2019526632A (ja) 2019-09-19
IL264924B1 (en) 2023-09-01
CN116473978A (zh) 2023-07-25
US20190209581A1 (en) 2019-07-11
JP2023052108A (ja) 2023-04-11
AU2017321011A1 (en) 2019-02-21
KR20190042591A (ko) 2019-04-24
IL305136A (en) 2023-10-01

Similar Documents

Publication Publication Date Title
IL264924A (https=)
CN303580171S (https=)
CN303537601S (https=)
CN303628090S (https=)
CN303622602S (https=)
CN303618816S (https=)
CN303589827S (https=)
CN303586094S (https=)
CN303583863S (https=)
CN303654984S (https=)
CN303573870S (https=)
CN303553845S (https=)
CN303536284S (https=)
CN303538754S (https=)
CN303538744S (https=)
CN303538723S (https=)
CN303536357S (https=)
CN303538699S (https=)
CN303538593S (https=)
CN303538553S (https=)
CN303538541S (https=)
CN303538471S (https=)
CN303538456S (https=)
CN303538367S (https=)
CN303538295S (https=)